Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Holding LLY?
Track your performance easily
LLY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$516.57 - $972.53
Previous Close$906.18
Volume1.78M
Average Volume (3M)3.20M
Market Cap
$861.26B
Enterprise Value$886.86B
Total Cash (Recent Filing)$3.36B
Total Debt (Recent Filing)$28.89B
Price to Earnings (P/E)115.4
Beta0.46
Next Earnings
Oct 30, 2024EPS Estimate
$4.49Last Dividend Ex-Date
Aug 15, 2024Dividend Yield0.54%
Share Statistics
EPS (TTM)8.01
Shares Outstanding950,425,778
10 Day Avg. Volume2,412,406
30 Day Avg. Volume3,199,533
Standard Deviation0.09
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)63.50
Price to Sales (P/S)22.55
Price to Cash Flow (P/CF)149.70
P/FCF Ratio909.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.79
Enterprise Value/Gross Profit32.80
Enterprise Value/Ebitda81.93
Forecast
1Y Price Target
$1,039.88Price Target Upside14.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
EarningsAnalyst resumes coverage with a Buy rating and a price target of $1,060 per share, driven by increased tirzepatide forecasts based on latest reported sales, script trends, and guidance.
Market ExpansionManagement believes that the self-pay market in the US will become a larger share of sales, indicating a significant growth opportunity in the future.
Pipeline DevelopmentsLilly announced positive topline Phase III results for once weekly insulin efsitora.
Bears Say
Patent ExpiryThe patent of one of Lilly’s key products, Trulicity, will expire in 2027, which could significantly impact its revenue, as the product contributed 21% of group sales in 2023.
Regulatory ChallengesEMA's CHMP adopted a negative opinion for Leqembi and recommended the EC to not grant marketing authorization in the EU, which raises concerns about similar outcomes for other products under review.
Supply Chain IssuesComments at the JPM24 conference indicated that tirzep capacity will continue to be a bottleneck for the foreseeable future, potentially hindering growth.
---
Ownership Overview
10.90% Insiders
24.54% Mutual Funds
43.99% Other Institutional Investors
20.56% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $516.57 and its highest was $972.53 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Aug 08, 2024. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.743 by $1.177.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 0.54%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is $4.49.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 950,425,800 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $3.92 in its last earnings report, beating expectations of $2.743. Following the earnings report the stock price went up 9.477%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 18B.
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,039.88 (14.91% Upside)
$1,039.88 (14.91% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $757.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.47%
12-Months-Change
Fundamentals
Return on Equity
59.63%
Trailing 12-Months
Asset Growth
31.12%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q2 2024
0:00 / 0:00
---
LLY Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
LLY Stock 12 Month Forecast
Average Price Target
$1,039.88
▲(14.91% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
29/29 ratings generated profit
1 Year Average Return
+58.60%
reiterated a buy rating 23 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +58.60% per trade.
---